Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Recipient : Newport Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Wellspring Ophthalmics’ newly acquired proprietary broad formulation platform is an innovative suspension comprising aqueous, amorphous nanodispersions of cyclosporine. These formulations are designed to have higher bioavailability for better efficacy ...
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
March 23, 2022
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Recipient : Newport Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?